증식성 당뇨망막병증 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Proliferative Diabetic Retinopathy Market size is expected to reach USD 8.21 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 8.66% during 2026-2034.

The Global Proliferative Diabetic Retinopathy Market is growing steadily due to the increasing global burden of diabetes and related complications. Proliferative diabetic retinopathy (PDR) is a severe eye condition that can lead to vision loss if untreated. Rising awareness regarding diabetic eye screening and advancements in retinal imaging technologies are supporting early detection and treatment. Expanding healthcare access in developing economies is also contributing to market growth.

Major drivers include the increasing adoption of anti-VEGF therapies, laser photocoagulation procedures, and vitrectomy surgeries. Pharmaceutical innovation and clinical research are enhancing treatment effectiveness and patient outcomes. Additionally, improved screening programs and tele-ophthalmology services are enabling timely diagnosis, particularly in remote areas. The growing diabetic population, especially in Asia-Pacific and North America, significantly supports sustained demand for PDR treatment solutions.

Future prospects appear promising with advancements in biologics, sustained-release drug delivery systems, and gene-based therapies. Artificial intelligence-assisted retinal screening tools are expected to improve diagnostic efficiency. Increasing public health initiatives targeting diabetes management will further expand treatment coverage. As early intervention becomes more accessible, the proliferative diabetic retinopathy market is projected to maintain steady growth over the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Anti-VEGF Agents
• Corticosteroids

By Mode of Administration

• Injectable
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Genentech Inc, Novartis AG, Regeneron Pharmaceuticals Inc, Pfizer Inc, Merck KGaA, Cipla Inc, AbbVie Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences, Intas Pharmaceuticals Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Anti-VEGF Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mode Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Mode Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Mode Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Mode Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Mode Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Mode Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Genentech Inc
  • 9.2.2 Novartis AG
  • 9.2.3 Regeneron Pharmaceuticals Inc
  • 9.2.4 Pfizer Inc
  • 9.2.5 Merck KGaA
  • 9.2.6 Cipla Inc
  • 9.2.7 AbbVie Inc
  • 9.2.8 Bausch Health Companies Inc
  • 9.2.9 Santen Pharmaceutical Co. Ltd
  • 9.2.10 Alimera Sciences
  • 9.2.11 Intas Pharmaceuticals Ltd